The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Three

Key Opinion Leaders Help to Foster Robust, Viable Pharmaceutical and Biotechnology Pipelines

Imagine a world where pharmaceutical and biotechnology companies developed therapies without input from KOLs at various stages of product discovery and development. The results would be far fewer treatments available, greater risks for unwanted side effects and potentially, a larger number of unnecessary therapies.
The average pharmaceutical company will initiate over 100 research projects to develop one successful compound. With the stakes high to create therapies that make a difference, pharmaceutical and biotechnology companies turn to KOLs for assistance in the following areas:

· Determining the medical needs for a disease early in the development of a compound
· Consulting on early clinical data as to the viability of a compound
· Providing guidance on how to present clinical data to practicing physicians in the community.

Next week’s fourth installment of the series by Kristen Smithwick will share how pharmaceutical and biotechnology companies contribute to the continued education and advancement of KOLs, clinical investigators and practicing physicians.

More Posts

Technology is Getting Smarter

By Paul Meade, Patient Engagement Lead  It has become apparent that in order for a healthcare organization to succeed, they need to be able to


Send Us A Message